Infinity Pharmaceuticals Stock Fundamentals
Infinity Pharmaceuticals fundamentals help investors to digest information that contributes to Infinity Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Infinity Stock. The fundamental analysis module provides a way to measure Infinity Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Infinity Pharmaceuticals stock.
Infinity |
Infinity Pharmaceuticals Company Operating Margin Analysis
Infinity Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Infinity Pharmaceuticals Operating Margin | (15.70) % |
Most of Infinity Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Infinity Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, Infinity Pharmaceuticals has an Operating Margin of -15.7049%. This is 55.23% lower than that of the Biotechnology sector and 85.99% lower than that of the Health Care industry. The operating margin for all United States stocks is 185.03% higher than that of the company.
Infinity Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Infinity Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Infinity Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Infinity Pharmaceuticals competition to find correlations between indicators driving Infinity Pharmaceuticals's intrinsic value. More Info.Infinity Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Infinity Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Infinity Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Infinity Pharmaceuticals' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Infinity Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Infinity Pharmaceuticals by comparing valuation metrics of similar companies.Infinity Pharmaceuticals is currently under evaluation in operating margin category among its peers.
Infinity Fundamentals
Return On Equity | -35.21 | |||
Return On Asset | -0.61 | |||
Operating Margin | (15.70) % | |||
Current Valuation | (9.46 M) | |||
Shares Outstanding | 90.76 M | |||
Shares Owned By Insiders | 2.36 % | |||
Shares Owned By Institutions | 23.48 % | |||
Number Of Shares Shorted | 2.21 M | |||
Price To Earning | (1.63) X | |||
Price To Book | 8.03 X | |||
Price To Sales | 19.29 X | |||
Revenue | 2.59 M | |||
Gross Profit | (31.38 M) | |||
EBITDA | (44.84 M) | |||
Net Income | (44.37 M) | |||
Cash And Equivalents | 56.58 M | |||
Cash Per Share | 0.63 X | |||
Total Debt | 917 K | |||
Debt To Equity | 0.13 % | |||
Current Ratio | 4.16 X | |||
Book Value Per Share | (0.41) X | |||
Cash Flow From Operations | (42.43 M) | |||
Short Ratio | 0.31 X | |||
Earnings Per Share | (0.45) X | |||
Price To Earnings To Growth | (0.05) X | |||
Target Price | 0.3 | |||
Number Of Employees | 30 | |||
Beta | 1.38 | |||
Market Capitalization | 2.63 M | |||
Total Asset | 42.15 M | |||
Retained Earnings | (855.95 M) | |||
Working Capital | 26.67 M | |||
Current Asset | 254.7 M | |||
Current Liabilities | 70.06 M | |||
Z Score | -29.4 | |||
Net Asset | 42.15 M |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Infinity Stock
If you are still planning to invest in Infinity Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Infinity Pharmaceuticals' history and understand the potential risks before investing.
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |